N/A N=88 Comparison of Noninvasive Hemoglobin Disposable Sensors
Healthy
Primary: Accuracy of Noninvasive Sensors by Arms Calculation — 1.0; 1.0 g/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=92 Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Leukemia, Myeloid, Acute · Leukemia, Myelogenous, Chronic · Leukemia, Lymphoblastic, Acute
Primary: Proportion of Donors From Whom a Sufficient Number of Cells for Transplantation Are Collected in no More Than 2 LP Procedures Following Mobilization With AMD3100 (Donor…
Phase 4 N=2 Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
Erythromelalgia
Primary: Carbamazepine Affects Pain in Patients With S241T NaV1.7 IEM Mutation — 3015; 136; 6360; 915 minutes
N/A N=51 Accuracy of Methemoglobin Measurement for Rainbow Universal Pulse Oximeter Sensor
Healthy
Primary: Accuracy of Sensor by Arms Calculation — 0.63 Percentage of total hemoglobin
N/A N=354 Accuracy of Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI)
Healthy
Primary: Accuracy of Sensor by Arms Calculation — 1.0 g/dL
Phase 2 N=18 Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea
Sleep Apnea, Obstructive
Primary: Apnea Hypopnea Index (AHI) — 39.1; 40.8 events/hour — p=>0.5
Phase 2 N=24 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
Neurofibromatosis 1
Primary: 3D Photographic Measurement of Surface Volume of Cutaneous Neurofibroma Lesion — 32.54; 33.93 mm^3
Phase 2 N=24 D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents
Posttraumatic Stress Disorder · PTSD
Primary: Child PTSD Symptom Scale (CPSS) — 20.4; 11.0 units on a scale
N/A N=143 Study Evaluating the Impact of Mesh Pore Size on Chronic Pain After Lichtenstein Hernioplasty
Inguinal Hernia
Primary: Chronic Pain — 34.3; 46.3 percentage of patients with pain
Phase 3 N=131 High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms
Schizophrenia
Primary: Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial — 633; 588 side effect events
Phase 2 N=20 Lorcaserin for Preventing Weight Gain Among Smokers
Tobacco Use Disorder · Weight Gain
Primary: Post Cessation Weight Change — 1.1 kg
Phase 2 N=24 Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer
Adenocarcinoma of the Prostate · Stage II Prostate Cancer · Stage III Prostate Cancer
Primary: Incidence of Acute and Chronic Grade 3 or Greater Toxicity as Evaluated Using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)…
N/A N=118 Accuracy of Hemoglobin Measurement for Various Rainbow Pulse Oximeter Sensors
Healthy
Primary: Accuracy of Sensor by Arms Calculation — 0.96 g/dL
Phase 2 N=147 Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Asthma
Primary: Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment Period — -0.002; -0.001; -0.034; -0.031 Liters
N/A N=141 Absolute Pro® MOMENTUM™
Peripheral Artery Disease · Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 0.0; 0.0; 0.0 percentage of participants